Cancer Diagnostics Market Research Report by Diagnostic Type (Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers), by Indication (Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, and Kidney Cancer) - Global Forecast to 2025 - Cumulative Impact of COVID-19
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Cancer Diagnostics Market is expected to grow from USD 151,315.82 Million in 2020 to USD 221,237.88 Million by the end of 2025.
2. The Global Cancer Diagnostics Market is expected to grow from EUR 132,676.58 Million in 2020 to EUR 193,985.58 Million by the end of 2025.
3. The Global Cancer Diagnostics Market is expected to grow from GBP 117,949.77 Million in 2020 to GBP 172,453.60 Million by the end of 2025.
4. The Global Cancer Diagnostics Market is expected to grow from JPY 16,149,232.51 Million in 2020 to JPY 23,611,688.47 Million by the end of 2025.
5. The Global Cancer Diagnostics Market is expected to grow from AUD 219,730.69 Million in 2020 to AUD 321,266.83 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Diagnostic Type, the Cancer Diagnostics Market studied across Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers.
Based on Indication, the Cancer Diagnostics Market studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.
Based on Geography, the Cancer Diagnostics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Diagnostics Market including Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson & Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic Inc., Illumina Inc., Philips Healthcare, Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc..
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Diagnostics Market?
6. What are the modes and strategic moves considered suitable for entering the Global Cancer Diagnostics Market?
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Cancer Diagnostics Market is expected to grow from USD 151,315.82 Million in 2020 to USD 221,237.88 Million by the end of 2025.
2. The Global Cancer Diagnostics Market is expected to grow from EUR 132,676.58 Million in 2020 to EUR 193,985.58 Million by the end of 2025.
3. The Global Cancer Diagnostics Market is expected to grow from GBP 117,949.77 Million in 2020 to GBP 172,453.60 Million by the end of 2025.
4. The Global Cancer Diagnostics Market is expected to grow from JPY 16,149,232.51 Million in 2020 to JPY 23,611,688.47 Million by the end of 2025.
5. The Global Cancer Diagnostics Market is expected to grow from AUD 219,730.69 Million in 2020 to AUD 321,266.83 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Cancer Diagnostics to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Diagnostic Type, the Cancer Diagnostics Market studied across Biopsy and Cytology Test, Diagnostic Imaging Test, and Tumor Biomarkers.
Based on Indication, the Cancer Diagnostics Market studied across Blood Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, and Skin Cancer.
Based on Geography, the Cancer Diagnostics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Cancer Diagnostics Market including Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson & Company, F. Hoffmann-La Roche Ltd, GE Healthcare, Hologic Inc., Illumina Inc., Philips Healthcare, Qiagen NV, Siemens Healthcare GmbH, and Thermo Fisher Scientific Inc..
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Cancer Diagnostics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Cancer Diagnostics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Cancer Diagnostics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Cancer Diagnostics Market?
4. What is the competitive strategic window for opportunities in the Global Cancer Diagnostics Market?
5. What are the technology trends and regulatory frameworks in the Global Cancer Diagnostics Market?
6. What are the modes and strategic moves considered suitable for entering the Global Cancer Diagnostics Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Diagnostic Type Outlook
3.4. Indication Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE
6.1. Introduction
6.2. Biopsy and Cytology Test
6.3. Diagnostic Imaging Test
6.4. Tumor Biomarkers
7. GLOBAL CANCER DIAGNOSTICS MARKET, BY INDICATION
7.1. Introduction
7.2. Blood Cancer
7.3. Breast Cancer
7.4. Cervical Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Ovarian Cancer
7.10. Pancreatic Cancer
7.11. Prostate Cancer
7.12. Skin Cancer
8. AMERICAS CANCER DIAGNOSTICS MARKET
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand
10. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. COMPETITIVE LANDSCAPE
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitor SWOT Analysis
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion
12. COMPANY USABILITY PROFILES
12.1. Abbott Laboratories
12.2. Agilent Technologies Inc.
12.3. Becton Dickinson & Company
12.4. F. Hoffmann-La Roche Ltd
12.5. GE Healthcare
12.6. Hologic Inc.
12.7. Illumina Inc.
12.8. Philips Healthcare
12.9. Qiagen NV
12.10. Siemens Healthcare GmbH
12.11. Thermo Fisher Scientific Inc.
13. APPENDIX
13.1. Discussion Guide
13.2. License & Pricing
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Diagnostic Type Outlook
3.4. Indication Outlook
3.5. Geography Outlook
3.6. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.2. Restraints
5.1.3. Opportunities
5.1.4. Challenges
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. GLOBAL CANCER DIAGNOSTICS MARKET, BY DIAGNOSTIC TYPE
6.1. Introduction
6.2. Biopsy and Cytology Test
6.3. Diagnostic Imaging Test
6.4. Tumor Biomarkers
7. GLOBAL CANCER DIAGNOSTICS MARKET, BY INDICATION
7.1. Introduction
7.2. Blood Cancer
7.3. Breast Cancer
7.4. Cervical Cancer
7.5. Colorectal Cancer
7.6. Kidney Cancer
7.7. Liver Cancer
7.8. Lung Cancer
7.9. Ovarian Cancer
7.10. Pancreatic Cancer
7.11. Prostate Cancer
7.12. Skin Cancer
8. AMERICAS CANCER DIAGNOSTICS MARKET
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. South Korea
9.10. Thailand
10. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. COMPETITIVE LANDSCAPE
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis
11.4. Competitor SWOT Analysis
11.5. Competitive Scenario
11.5.1. Merger & Acquisition
11.5.2. Agreement, Collaboration, & Partnership
11.5.3. New Product Launch & Enhancement
11.5.4. Investment & Funding
11.5.5. Award, Recognition, & Expansion
12. COMPANY USABILITY PROFILES
12.1. Abbott Laboratories
12.2. Agilent Technologies Inc.
12.3. Becton Dickinson & Company
12.4. F. Hoffmann-La Roche Ltd
12.5. GE Healthcare
12.6. Hologic Inc.
12.7. Illumina Inc.
12.8. Philips Healthcare
12.9. Qiagen NV
12.10. Siemens Healthcare GmbH
12.11. Thermo Fisher Scientific Inc.
13. APPENDIX
13.1. Discussion Guide
13.2. License & Pricing
LIST OF TABLES
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY AND CYTOLOGY TEST, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TEST, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR BIOMARKERS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. GLOBAL CANCER DIAGNOSTICS MARKET: SCORES
TABLE 80. GLOBAL CANCER DIAGNOSTICS MARKET: BUSINESS STRATEGY
TABLE 81. GLOBAL CANCER DIAGNOSTICS MARKET: PRODUCT SATISFACTION
TABLE 82. GLOBAL CANCER DIAGNOSTICS MARKET: RANKING
TABLE 83. GLOBAL CANCER DIAGNOSTICS MARKET: MERGER & ACQUISITION
TABLE 84. GLOBAL CANCER DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 85. GLOBAL CANCER DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 86. GLOBAL CANCER DIAGNOSTICS MARKET: INVESTMENT & FUNDING
TABLE 87. GLOBAL CANCER DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 88. GLOBAL CANCER DIAGNOSTICS MARKET: LICENSE & PRICING
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY AND CYTOLOGY TEST, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TEST, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR BIOMARKERS, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 20. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 21. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 22. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 23. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 24. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 25. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 26. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 27. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 28. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 29. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 30. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 31. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 32. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 33. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 34. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 35. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 36. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 37. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 38. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 39. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 40. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 41. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 42. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 43. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 44. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 45. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 46. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 47. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 48. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 49. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 50. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 51. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 52. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 53. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 54. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 55. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 56. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 57. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 58. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 59. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 60. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 61. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 62. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 63. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 64. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 65. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 66. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 67. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 68. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 69. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 70. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 71. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 72. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 73. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 74. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 75. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 76. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 77. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 78. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 79. GLOBAL CANCER DIAGNOSTICS MARKET: SCORES
TABLE 80. GLOBAL CANCER DIAGNOSTICS MARKET: BUSINESS STRATEGY
TABLE 81. GLOBAL CANCER DIAGNOSTICS MARKET: PRODUCT SATISFACTION
TABLE 82. GLOBAL CANCER DIAGNOSTICS MARKET: RANKING
TABLE 83. GLOBAL CANCER DIAGNOSTICS MARKET: MERGER & ACQUISITION
TABLE 84. GLOBAL CANCER DIAGNOSTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 85. GLOBAL CANCER DIAGNOSTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 86. GLOBAL CANCER DIAGNOSTICS MARKET: INVESTMENT & FUNDING
TABLE 87. GLOBAL CANCER DIAGNOSTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 88. GLOBAL CANCER DIAGNOSTICS MARKET: LICENSE & PRICING
LIST OF FIGURES
FIGURE 1. GLOBAL CANCER DIAGNOSTICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER DIAGNOSTICS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2020 (USD MILLION)
FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2020 (USD MILLION)
FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 11. GLOBAL CANCER DIAGNOSTICS MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL CANCER DIAGNOSTICS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2020 VS 2025 (%)
FIGURE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2020 VS 2025 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2025
FIGURE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY AND CYTOLOGY TEST, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TEST, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR BIOMARKERS, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2020 VS 2025 (%)
FIGURE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2020 VS 2025 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025
FIGURE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 26. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 31. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 32. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 33. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 34. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 36. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 37. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 42. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 44. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 51. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 55. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 56. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 57. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 62. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 63. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 64. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. GLOBAL CANCER DIAGNOSTICS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 68. GLOBAL CANCER DIAGNOSTICS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 69. GLOBAL CANCER DIAGNOSTICS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 70. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CANCER DIAGNOSTICS MARKET, BY TYPE
FIGURE 1. GLOBAL CANCER DIAGNOSTICS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER DIAGNOSTICS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2020 (USD MILLION)
FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2020 (USD MILLION)
FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 10. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 11. GLOBAL CANCER DIAGNOSTICS MARKET: MARKET DYNAMICS
FIGURE 12. GLOBAL CANCER DIAGNOSTICS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2020 VS 2025 (%)
FIGURE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2020 VS 2025 (USD MILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC TYPE, 2025
FIGURE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BIOPSY AND CYTOLOGY TEST, 2020 VS 2025 (USD MILLION)
FIGURE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC IMAGING TEST, 2020 VS 2025 (USD MILLION)
FIGURE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TUMOR BIOMARKERS, 2020 VS 2025 (USD MILLION)
FIGURE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2020 VS 2025 (%)
FIGURE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2020 VS 2025 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY INDICATION, 2025
FIGURE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BLOOD CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CERVICAL CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 26. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY KIDNEY CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 27. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LIVER CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 28. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 29. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY OVARIAN CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PANCREATIC CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 31. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 32. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SKIN CANCER, 2020 VS 2025 (USD MILLION)
FIGURE 33. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 34. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 35. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 36. ARGENTINA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 37. BRAZIL CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. CANADA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. MEXICO CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. UNITED STATES CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 42. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 43. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 44. AUSTRALIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. CHINA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 46. INDIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 47. INDONESIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 48. JAPAN CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 49. MALAYSIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 50. PHILIPPINES CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 51. SOUTH KOREA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 52. THAILAND CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 53. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 54. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 55. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 56. FRANCE CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 57. GERMANY CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 58. ITALY CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 59. NETHERLANDS CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 60. QATAR CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 61. RUSSIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 62. SAUDI ARABIA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 63. SOUTH AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 64. SPAIN CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 65. UNITED ARAB EMIRATES CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 66. UNITED KINGDOM CANCER DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 67. GLOBAL CANCER DIAGNOSTICS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 68. GLOBAL CANCER DIAGNOSTICS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 69. GLOBAL CANCER DIAGNOSTICS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 70. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL CANCER DIAGNOSTICS MARKET, BY TYPE
